Press Release

Timo Lindemann
Group Communications

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 1511 5515324
timo.lindemann@fresenius.com
www.fresenius.com

November 13, 2026

Fresenius receives Building Public Trust Award for outstanding sustainability reporting

Transparent, credible, and consistent: Global healthcare company Fresenius has received the Building Public Trust Award in the DAX 40 category for its sustainability reporting. The award recognizes credible and exemplary reporting in accordance with the EU's Corporate Sustainability Reporting Directive (CSRD).

"Sustainability is part of our DNA as a healthcare company. Consistent reporting provides transparency on our material sustainability topics. This helps us make the right decisions and drive focused improvements," said Dr. Michael Moser, member of the Fresenius Management Board. Sustainability is an integral part of the #FutureFresenius strategy.

To highlight particularly compelling reporting practices, the independent jury assessed criteria including the identification of material sustainability topics, the presentation of impacts, risks, and opportunities, and the structure and clarity of the information provided. For the award, organized by the Sustainable Finance Research Group (SFRG), the jury evaluated the annual and sustainability reports of 89 companies from the DAX 40, MDAX, and SDAX.

# # #

Related Links

Fresenius Sustainability Statement 2025

About Fresenius

Fresenius (XFRA: FRE, OTC: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, medical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe's largest private hospital operator, treating around 27 million patients annually.

With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.

For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.

Fresenius Medical Care AG is an independent, separately listed company (XETR: FME; NYSE: FMS), in which Fresenius SE & Co. KGaA holds a financial investment; Fresenius Medical Care's results are not consolidated in the Fresenius Group's revenue and earnings.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Sara Hennicken, Dr. Marc-Alexander Mahl,
Dr. Michael Moser, Dr. Christian Pawlu
Chairman of the Supervisory Board: Wolfgang Kirsch